Reflections From J.P. Morgan: Challenges As Always And Reasons For Optimism
Executive Summary
Biopharma investors were underwhelmed by the deal-making news, but innovation, corporate tax reform and a relatively positive outlook on drug pricing left attendees at the J.P. Morgan Healthcare Conference with the sense that good things are in store for pharma in 2018.
You may also be interested in...
Celgene's $1.1bn Impact Buy Is First Of More Deals To Come In 2018 And Beyond
Celgene believes it's acquiring a $1bn drug, not a me-too JAK inhibitor in its purchase of Impact Biomedicines for $1.1bn up front. Investors appeared skeptical of fedratinib's potential, but the company said at the J.P. Morgan meeting that it will execute more deals to build out its pipeline.
Spark's Luxturna Approval Ushers In A New Gene Therapy Era
Spark's gene therapy for patients with an inherited form of blindness will be available in the US late in the first quarter, but on the big question – whether it will cost $1m for the one-time treatment – Spark would not say.
Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan
Pharmaceutical manufacturers have been waiting for Trump’s ax to fall – and it finally did, on the final full day of the industry’s biggest business meeting of the year.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: